Skip to main content
. 2019 Jan 3;30(2):355–365. doi: 10.1681/ASN.2018060656

Table 4.

Dual-energy x-ray absorptiometry and high-resolution peripheral quantitative computed tomography parameters in the zoledronate and control groups

Parameter Control Baseline Control 12 mo Changes,a Absolute/% Zoledronate Baseline Zoledronate 12 mo Changes,a Absolute/% P Value Transplant P Value Zoledronate versus Control P Value Interaction
BMD lumbar spine, g/cm2 0.95±0.13 0.96±0.13 0.01/1.05 0.90±0.14 0.95±0.13 0.05/5.6 <0.01 0.63 0.04
BMD total hip, g/cm2 0.89±0.14b 0.96±0.13 0.07/7.9 0.80±0.14 0.90±0.20 0.1/12.5 <0.001 0.55 0.15
BMD femoral neck, g/cm2 0.79±0.14 0.81±0.14 0.02/2.5 0.69±0.14 0.73±0.11 0.04/5.8 0.001 0.28 0.03
HR-pQCT tibia
 Tt.vBMD, mg HA/cm3 282±48b 278±42 −4/−1.4 239±67 236±64 −3/−1.3 0.03 0.14 0.35
 Tb.vBMD, mg HA/cm3 148±41b 144±32 −4/−2.7 117±32 115±33 −2/−1.7 0.04 0.02 0.53
 Ct.vBMD, mg HA/cm3 895±86 898±95 3/0.3 870±101 865±95 −5/−0.6 0.55 0.41 0.61
 BV/TV, % 12.3±3.2 11.8±2.7 −0.5/−4.1 9.8±2.7 9.5±2.7 −0.3/−3.1 0.78 <0.001 0.94
 Tb.N,1/mm 1.58±0.25 1.60±0.29 0.02/1.3 1.34±0.32 1.45±0.40 0.11/8.2 0.10 0.02 0.38
 Tb.Th, mm 0.08±0.01 0.07±0.01 −0.01/−12.5 0.07±0.01 0.07±0.01 0/0 0.02 0.48 0.34
 Tb.Sp, mm 0.57±0.11b 0.57±0.11 0/0 0.72±0.20 0.69±0.26 −0.03/−4.2 0.20 0.01 0.69
 Ct.Th, mm 1.20±0.23 1.19±0.21 −0.1/−8.3 1.02±0.33 1.03±0.32 0.1/9.8 0.98 0.16 0.73
 Ct.Po, % 5.0±4.2 5.2±4.3 0.2/4 5.0±3.8 4.8±2.9 −0.2/−4 0.87 0.91 0.29
 S, kN/mm 222.5±65.7 217.7±60.9 −7.8/−3.5 192.5±63.6 189.4±62.6 −3.1/−1.6 0.20 0.19 0.78
 F.ult, kN 58.8±39.3 58.1±39.1 −0.7/−1.2 51.5±35.3 51.0±34.9 −0.5/−1.0 0.88 0.56 0.98
HR-pQCT radius
 Tt.vBMD, mg HA/cm3 322±69 317±69 −5/−1.6 274±93 264±91 −10/−3.6 0.08 0.07 0.62
 Tb.vBMD, mg HA/cm3 182±55 173±48 −9/−4.9 153±49 145±48 −8/−5.2 0.02 0.14 0.99
 Ct.vBMD, mg HA/cm3 837±121 839±118 2/0.2 799±122 798±107 −1/−0.1 0.97 0.27 0.86
 BV/TV, % 14.6±4.8 14.8±4.1 0.2/1.4 12.8±3.8 12.1±4.0 −0.7/−5.5 0.01 0.13 0.98
 Tb.N, 1/mm 1.95±0.40 2.05±0.29 0.1/5.1 1.83±0.37 1.92±0.35 0.09/4.9 0.06 0.36 0.80
 Tb.Th, mm 0.08±0.02 0.07±0.01 −0.01/−12.5 0.07±0.02 0.06±0.02 −0.01/−14.2 0.001 0.18 0.67
 Tb.Sp, mm 0.46±0.13 0.43±0.08 −0.03/−6.5 0.50±0.14 0.48±0.13 −0.02/−4 0.07 0.50 0.68
 Ct.Th, mm 0.71±0.22 0.72±0.22 0.1/14 0.61±0.30 0.60±0.27 −0.01/−1.6 >0.99 0.20 0.69
 Ct.Po, % 2.9±2.5 3.1±2.5 0.2/6.9 2.4±1.4 2.2±1.3 −0.2/−8.3 0.94 0.32 0.25
 S, kN/mm 87.6±25 86.0±25.5 −1.6/−1.8 75.6±33.4 75.5±28.2 −0.1/−0.3 >0.99 0.29 0.34
 F.ult, kN 42.4±14.4 43.5±13.1 1.1/2.6 35.3±12.5 34.7±10.7 −0.6/−1.7 0.84 0.31 0.32

Continuous variables are presented as mean ± SD. P values are derived from a linear mixed model. BMD, bone mineral density; HR-pQCT, high-resolution peripheral quantitative computed tomography; Tt.vBMD, total volumetric bone mineral density; HA, hydroxyapatite; Tb.vBMD, trabecular volumetric bone mineral density; Ct.vBMD, cortical volumetric bone mineral density; BV/TV, trabecular bone volume/total volume; Tb.N, number of trabeculae; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Ct.Th, cortical thickness; Ct.Po, cortical porosity; S, stiffness; F.ult, estimated failure load.

a

Changes according to groups.

b

P<0.05 control versus zoledronate at baseline (tested by unpaired t test or Mann–Whitney as appropriate).